WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount t
Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics c
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, P
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.10 per share, beating the Zacks Consensus Estimate of $5.93 per share. This compares to earnings of $5.67 per share a year ago.
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue, helped by improved demand for its products and services used in developing therapies.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended Decembe
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.
Investors focused on top-and-bottom-line performance—important as they are—do so at the risk of neglecting another crucial metric for companies across industries: cash flow. Put simply, without ad
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
Thermo Fisher Scientific is poised for growth in 2025, driven by aging demographics, higher healthcare spending, and demand for innovative biological medicines. TMO's diverse revenue streams, includin
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE